I went to Wimbledon for the tennis recently, and I was struck by a system they have in operation for allowing people to queue for returned tickets, in order to get as many people in to watch the matches as possible.

It got me thinking that having an effective wait list system in place for trials would seem like a good idea. Now, of course, the biggest problem is recruiting enough patients in the first place. But in situations where there are a large number of potential trial participants, I’d say it could make sense to continue with the recruitment process – at a reduced level – even after the required number of patients have been recruited.

This can help you with replacements for the inevitable drop-outs from the trial, plus potentially provide a database of willing participants for future trials in the same area.

You may also like

Biotech C-suites Should keep Patient Recruitment in Mind from the Outset
In biotech, a strong C-suite isn’t just about job titles - it’s about covering every part of the journey from discovery to delivery. Including being prepared to tackle one of the biggest ...
Key C-suite Roles for Biotech Success - The Chief Patient Recruitment Officer (CPRO)
While biotech companies have built C-suites with scientific, medical, financial, operational, and business expertise, a critical function has remained conspicuously absent - addressing one ...
Key C-suite Roles for Biotech Success - The Chief Business Officer (CBO)
The Chief Business Officer leads external strategy - licensing deals, identifying pharma partnerships, and developing long-term growth planning and market positioning strategies that ...